Revolutionary. A game changer. Spine chilling. Those are some of the words experts used to describe fresh data for lenacapavir, a twice-yearly shot developed by Gilead Sciences for the prevention of HIV. Their enthusiasm stems from a more succinct word: zero. That’s the number of ...
